News

Ganaxolone is being developed in three different dose forms that include IV, capsule, and liquid, aimed at maximizing therapeutic reach to adult and pediatric patient populations in both acute and chronic

The 16-subject FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial will assess 50 mg of CBD in ZYN002 4.2% gel once daily. It

Upon completion of the transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of BiondVax. Angels Investments is owned by Check Point co-founder and

Together the two companies are projected to generate approximately $136 million dollars in revenue in 2016 and are projecting $156 million in revenue for 2017. F.A.S.T. will retain

The deal, which was signed in June 2016, includes the transfer of Sanofi’s ownership of the €11.4bn Merial animal health business to Boehringer in return for the latter's

The study is enrolling patients with non-small cell lung cancer (NSCLC) who have failed prior therapy.  The trial will begin with a Phase 1 safety component, enrolling up

TetraLogic sold its SMAC mimetic program, including their clinical stage asset birinapant, and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir for a purchase price of $12m payable in

Following a preliminary review of the company's NDA for Xaracoll, filed in October 2016, the FDA concluded that the application was not sufficiently complete to allow for a more

The REACH-1 phase 2 trial is assessing ruxolitinib in combination with corticosteroids It has a primary endpoint defined as overall response rate at day 28 of the single-cohort clinical trial. Some